Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

In the management of neurological diseases, the identification and quantification of axonal
damage could allow for the improvement of diagnostic accuracy and prognostic assessment …

With the potential development of new disease-modifying Alzheimer's disease (AD)
therapies, simple, widely available screening tests are needed to identify which individuals …

Frontotemporal lobar degeneration (FTLD) is one of the most common causes of early-onset
dementia and presents with early social–emotional–behavioural and/or language changes …

The Alzheimer's disease (AD) afflicted brain is neuropathologically defined by extracellular
amyloid-β (Aβ) plaques and intraneuronal neurofibrillary tangles composed of …

Introduction A systematic review and meta-analysis was performed regarding the diagnostic
performance of neurofilament light chain (NfL) in CSF and blood. Methods A database …

Abstract Background In neurodegenerative dementias (NDs) such as prion disease,
Alzheimer's disease (AD), and frontotemporal lobar degeneration (FTLD), protein misfolding …

Alzheimer's disease is a progressive, clinically heterogeneous, and particularly complex
neurodegenerative disease characterized by a decline in cognition. Over the last two …

Abstract Chitinase‐3‐like protein 1 (CHI3L1/YKL‐40) has long been known as a biomarker
for early detection of neuroinflammation and disease diagnosis of Alzheimer's disease (AD) …

Neuropathological diagnostic criteria of neurodegenerative disorders are based on the
presence of specific inclusions in a specific area of brain tissue that correlate with clinical …